contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-extraordinary-general-meeting-of-inify-laboratories-ab

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Inify Laboratories provides cancer diagnostics through pathology laboratory services. The company uses a digital, standardized workflow for response times and quality assurance, initially in prostate diagnostics. Customers primarily consist of laboratories and hospitals. Inify Laboratories was founded in 2022 and is headquartered in Stockholm, Sweden.

Inify Laboratories

Today, December 4, 2025, an extraordinary general meeting was held in INIFY Laboratories AB, reg. no. 559345-4431 (the "Company"). At the meeting, 66,655,976 shares were represented, corresponding...

Today, December 4, 2025, an extraordinary general meeting was held in INIFY Laboratories AB, reg. no. 559345-4431 (the "Company"). At the meeting, 66,655,976 shares were represented, corresponding to 84.5 per cent of the total number of shares and votes in the Company. Below follows a summary of the resolution adopted at the meeting.Resolution on directed share issuesThe general meeting resolved, in accordance with the board of directors' proposal, on a directed issue of shares to SB1 Markets AS for onward transfer to major shareholders in the Company (the "Private Placement") and on a directed issue of shares to SB1 Markets AS for onward transfer to other shareholders in the Company (the "Repair Issue"). Details and timetable for the Private Placement and the Repair Issue are set out in the Company's press releases dated November 12, 2025 and December 3, 2025, respectively.&nbsp;For further information, contact: Ann-Charlotte Linderoth, CFO E-mail: <a href="mailto:ann-charlotte.linderoth@inify.com">ann-charlotte.linderoth@inify.com</a>&nbsp;###This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.###The future of diagnosticsInify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis.&nbsp; The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on <a href="https://live.euronext.com/en/product/equities/SE0017486103-MERK">Euronext Growth Oslo</a> under the ticker <a href="https://live.euronext.com/en/product/equities/SE0017486103-MERK">INIFY.</a>&nbsp;<div></div>